Unicycive Therapeutics Inc

NASDAQ:UNCYUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Nov 13, 2024

Show headlines and story abstract

• Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update, from 7:15AM ET on Wednesday Nov 13, 2024 by Dow Jones

  7:15AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: UNCY
  
  SOURCE: Unicycive Therapeutics, Inc.
  Unicycive Therapeutics, Inc. Balance Sheets (In thousands, except for share and per share amounts) As of As of December 31, September 30, 2023 2024 -------------- --------------- Assets (Unaudited) -------------- --------------- Current assets: Cash and cash equivalents $ 9,701 $ 32,347 Prepaid expenses and other current assets 3,698 5,394 --------- ---------- Total current assets 13,399 37,741 Right of use asset, net 766 772 Property, plant and equipment, net 26 61 --------- ---------- Total assets $ 14,191 $ 38,574 ========= ========== Liabilities and stockholders' (deficit) equity Current liabilities: Accounts payable $ 839 $ 548 Accrued liabilities 3,234 2,992 Warrant liability 13,134 6,377 Operating lease liability - current 327 542 --------- ---------- Total current liabilities 17,534 10,459 Operating lease liability -- long term 466 265 --------- ---------- Total liabilities 18,000 10,724 Commitments and contingencies Stockholders' (deficit) equity: Series A-2 Prime preferred stock, $0.001 par value per share -- 43,649 Series A-2 shares authorized at December 31, 2023 and 21,388.01 Series A-2 Prime shares authorized at September 30, 2024; 43,649 Series A-2 shares outstanding at December 31, 2023 and 11,111.24 Series A-2 Prime shares outstanding at September 30, 2024 - - Series B-2 preferred stock, $0.001 par value per share -- zero Series B-2 shares authorized at December 31, 2023 and 7,882 Series B-2 Prime shares authorized at September 30, 2024; zero Series B-2 shares outstanding at December 31, 2023 and 7,882 Series B-2 shares outstanding at September 30, 2024 - - Preferred stock: $0.001 par value per share--10,000,000 shares authorized at December 31, 2023 and September 30, 2024; zero shares issued and outstanding at December 31, 2023 and September 30, 2024 - - Common stock, $0.001 par value per share -- 200,000,000 shares authorized at December 31, 2023 and 400,000,000 shares authorized at September 30, 2024; 34,756,049 and 97,858,406 shares issued and outstanding at December 31, 2023 and September 30, 2024, respectively 35 98 Additional paid-in capital 60,697 107,497 Accumulated deficit (64,541) (79,745) --------- ---------- Total stockholders' (deficit) equity (3,809) 27,850 --------- ---------- Total liabilities and stockholders' (deficit) equity $ 14,191 $ 38,574 ========= ========== Unicycive Therapeutics, Inc. Statements of Operations (In thousands, except for share and per share amounts) (Unaudited) Three Months Ended September 30, ------------------------- 2023 2024 ----------- ----------- Operating expenses: Research and development $ 3,372 $ 3,045 General and administrative 2,566 3,206 ---------- ---------- Total operating expenses 5,938 6,251 ---------- ---------- Loss from operations (5,938) (6,251) Other income (expenses): Interest income 227 416 Interest expense (18) (15) Change in fair value of warrant liability 1,396 1,754 ---------- ---------- Total other income (expenses) 1,605 2,155 ---------- ---------- Net loss (4,333) (4,096) Deemed dividends to Series A-1 preferred stockholders (72) - ---------- ---------- Net loss attributable to common stockholders $ (4,405) $ (4,096) ========== ========== Net loss per share attributable to common stockholders, basic and diluted $ (0.13) $ (0.05) ========== ========== Weighted-average shares outstanding used in computing net loss per share, basic and diluted 32,633,074 88,943,212 ========== ==========
  

• Press Release: Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update, from 7:15AM ET on Wednesday Nov 13, 2024 by Dow Jones

  7:15AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: UNCY